Studies in other cancers have demonstrated that the addition of chemotherapy to PD-1/PD-L1 inhibitor improved ORR and clinical outcomes, with experts theorizing that such combination could exert a synergistic antitumor effect in patients (26, 27). The gene discussed is CD274; the disease is cancer.